| Updates to existing prior authorization programs | |||
| Drug | Products affected | Effective date | Policy & Additional Information |
| Avastin, Alymsys, Vegzelma | Tufts Health Plan Commercial, Tufts Health Direct, Tufts Health RITogether, Tufts Health Together | Jan. 1, 2024 | Bevacizumab Products |
| Botox, Dysport, Myobloc, Xeomin | Harvard Pilgrim commercial, Tufts Health Plan commercial, Tufts Heath Direct, Tufts Health RITogether | Jan. 1, 2024 | Botulinum Toxins (Harvard Pilgrim, Tufts Health Plan) |
| Elelyso | Harvard Pilgrim commercial, Tufts Health Plan commercial, Tufts Heath Direct | Jan. 1, 2024 | Cerezyme Elelyso VPRIV (Harvard Pilgrim, Tufts Health Plan) |
| Herceptin, Herceptin Hylecta, Herzuma, Ogivri, Ontruzant,
|
Harvard Pilgrim commercial, Tufts Health Plan commercial, Tufts Heath Direct, Tufts Health Together, Tufts Health RITogether | Jan. 1, 2024 | Trastuzumab Products (Tufts Health Plan) |
| Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima | Harvard Pilgrim commercial, Tufts Health Plan commercial, Tufts Health Direct, Tufts Heath Together, Tufts Health RITogether | Jan. 1, 2024 | Rituximab Products for Non-oncology Indications (Harvard Pilgrim commercial)
Rituximab Products for Non-oncology Indications (Tufts Health Plan commercial, Tufts Health Direct) Rituximab Products (Tufts Health Together, Tufts Health RITogether) Rituximab Products for Oncology Indications (Tufts Health Plan commercial, Tufts Health Direct) |
Audrey Kleinberg,
Director, Provider Relations & Communications
Annmarie Dadoly,
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Stephen Wong,
Writers
Kristin Edmonston,
Production Coordinator
Kristina Cicelova,
Graphic Designer